Friday, September 15, 2017 5:07:53 PM
From this Nov 2016 PR:
http://www.genengnews.com/gen-news-highlights/medivir-buys-two-cancer-candidates-from-tetralogic-for-up-to-238m/81253394
-Medivir said it has agreed to buy two clinical-stage cancer candidates and their related development programs from Tetralogic Pharmaceuticals for up to $238 million in an acquisition the buyer said will enhance its oncology pipeline.
-Medivir said it plans to launch a Phase III trial in the second half of next year (2017) for remetinostat, a topical HDAC inhibitor that the company said is strongly linked to its existing expertise in protease inhibition. Remetinostat is now under study in a late Phase II program designed to treat early-stage cutaneous T-cell lymphoma (CTCL)—a potential market that Medivir said has been estimated at approximately $900 million a year.
-Medivir has agreed to pay Tetralogic $12 million upfront, up to $20 million tied to remetinostat achieving development milestones through regulatory filings; up to $45 million tied to remetinostat winning regulatory approval milestones; and up to $31 million tied to achieving additional commercialization milestones, primarily related to sales. Medivir has also agreed to pay tiered royalties capped at an aggregate of 13% on remetinostat sales.
See the company power powerpoint here, pages 7-12:
http://www.medivir.se/v5/images/pdf/2017/Medivir-Corporate-Presentation-August-2017.pdf
It looks like Phase 2 was completed, and they have met with the FDA and will be announcing Phase 3 starting very soon. That could mean about $20-$65 million in milestones coming TLOG's way.
26 million shares Outstanding @ $0.02 = Only a $520,000 market cap.
All my math says this will be a $1+ stock based just on early milestones coming yet this year. Huge upside imo.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM